Studies of the Variable Phenotypic Presentations of Rapid-Onset Dystonia Parkinsonism and Other Movement Disorders
Launched by STATE UNIVERSITY OF NEW YORK AT BUFFALO · May 21, 2008
Trial Information
Current as of June 27, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is focused on understanding a rare condition called rapid-onset dystonia-parkinsonism (RDP), which affects a person's movement and muscle control. The study aims to find individuals who either have RDP or carry specific genetic changes related to the condition. Researchers want to learn more about how common RDP is and how it develops over time in those affected.
If you or someone you know has symptoms that match RDP or has been diagnosed with this condition, you may be eligible to participate in the trial. The study is open to people of all ages and genders, and they are currently looking for participants. There are no specific exclusions, meaning that if you meet the criteria, you can join. As a participant, you can expect to provide information about your health and possibly undergo tests to help researchers gather important data about this condition. Your involvement could help improve understanding and treatment options for RDP in the future.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • clinical presentation consistent with ATP1A3 disease (RDP, AHC) or confirmed diagnosis of RDP or AHC
- Exclusion Criteria:
- • none
About State University Of New York At Buffalo
The State University of New York at Buffalo (SUNY Buffalo) is a prominent research institution dedicated to advancing healthcare through innovative clinical trials and studies. Renowned for its commitment to academic excellence and interdisciplinary collaboration, the university leverages its extensive resources and expertise to explore novel therapeutic approaches and enhance patient outcomes. SUNY Buffalo's clinical trials encompass a wide range of medical disciplines, driven by a mission to translate research discoveries into practical applications that benefit diverse populations. With a focus on ethical standards and rigorous methodologies, the university fosters an environment that supports cutting-edge research while prioritizing participant safety and well-being.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Miami, Florida, United States
Sacramento, California, United States
Buffalo, New York, United States
Patients applied
Trial Officials
Allison Brashear, MD
Principal Investigator
Dean, University at Buffalo Jacobs School of Medicine and Biomedical Sciences
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials